CSIMarket Company Name, Ticker, Customers, else..
 
Century Therapeutics inc   (IPSC)
Other Ticker:  
 
 
Price: $1.4600 $-0.02 -1.351%
Day's High: $1.5 Week Perf: -9.32 %
Day's Low: $ 1.45 30 Day Perf: -5.19 %
Volume (M): 215 52 Wk High: $ 5.51
Volume (M$): $ 314 52 Wk Avg: $2.76
Open: $1.50 52 Wk Low: $1.28



 Market Capitalization (Millions $) 120
 Shares Outstanding (Millions) 82
 Employees 75
 Revenues (TTM) (Millions $) 2
 Net Income (TTM) (Millions $) -131
 Cash Flow (TTM) (Millions $) -22
 Capital Exp. (TTM) (Millions $) 5

Century Therapeutics Inc
Century Therapeutics Inc. is a clinical-stage biotechnology company that focuses on developing genetically engineered immune cells for cancer therapy. The company utilizes induced pluripotent stem cells (iPSCs) to create immune cells, such as T cells and natural killer (NK) cells, that have enhanced anti-tumor properties. By reprogramming these cells, Century aims to improve their efficacy and safety for use in cancer treatment. Their ultimate goal is to develop off-the-shelf cell therapies that can be readily available to treat a wide range of tumors. Century Therapeutics is based in Philadelphia, Pennsylvania, and was founded in 2018.


   Company Address: 25 N 38th Street, 11th Floor Philadelphia 19104 PA
   Company Phone Number: 817-5790   Stock Exchange / Ticker: NASDAQ IPSC


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

Century Therapeutics Innovative Cell Therapy, CNTY-101, Shows Promising Safety Profile and Outpatient Feasibility in...

Published Mon, Jun 3 2024 11:00 AM UTC

Century Therapeutics, a leading cell therapy company, has presented promising interim results from their Phase 1 ELiPSE-1 study at the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO). The results highlight the safety and efficacy of CNTY-101, a cutting-edge investigational cell therapy for the treatment of hematologic malignancies.During the ongoing d...
Century Therapeutics Inc

Century Therapeutics Inc Turns Losses Into Profits in Latest Financial Report



Century Therapeutics, a leading biotechnology company specializing in autoimmune diseases, recently released its financial results for the most recent fiscal period. These results indicate significant improvements in key performance indicators, along with a game-changing development in its iPSC derived NK cell therapy, CNTY-101. This article explores the implications of these results and their potential impact on the company going forward.
Positive Shifts in Key Financial Metrics:
The financial report reveals a string of positive developments for Century Therapeutics. Firstly, the company reduced its loss per share from $-0.53 to $-0.45, indicating a positive trajectory in its financial performance. Moreover, income per share improved from $-0.66 to an undisclosed value, showcasing a favorable trend.
Merger and Acquisition

Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics.

Published Thu, Apr 11 2024 11:00 AM UTC

Century Therapeutics, a leading biotechnology company in the field of autoimmune diseases, is making significant strides in its pursuit of additional regulatory filings for its cutting-edge iPSC derived iNK cell therapy, CNTY-101. The company's recent CALiPSO-1 trial in systemic lupus erythematosus (SLE) has shown promising results, prompting Century Therapeutics to explore ...
Century Therapeutics Inc

IPSC's Top-Line Takes a Dive as Fiscal Period Closes in December 2023

Century Therapeutics Inc (NASDAQ: CNTY) has seen a significant drop in its stock price in March 2024, with a decrease of 19.95% so far. However, over the past 12 months, the stock has still managed to increase by 3.76%. Currently, the stock is trading on the NASDAQ at a price that is 62.3% above its 52-week average.
These fluctuations in the stock price can be attributed to the company's financial performance. According to their fiscal period closing on December 31, 2023, Century Therapeutics Inc reported an increase in loss per share. The loss per share increased to $-0.66 compared to $-0.30 in the previous year, and the loss grew from $-0.55 in the preceding reporting season. The company's revenue also experienced a decline of 48.56% from $0.52 million to $0.27 million in the comparable reporting season a year prior. However, the revenue showed a sequential surge of 81.081% from $0.15 million.
Clinical Study

Century Therapeutics Showcases CAR iNK Therapy Potential Amid Revenue Decline

Published Sat, Dec 9 2023 5:00 PM UTC



Philadelphia-based biotechnology company Century Therapeutics Inc. recently presented initial data from the CNTY-101 Phase 1 ELiPSE-1 trial at the 65th ASH Annual Meeting. The results highlight the potential for a multi-dosing strategy for CAR iNK therapy enabled by allo-evasion edits. In addition, the therapy was found to be generally well tolerated in a high-risk...






Century Therapeutics Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com